Cancer of the urinary bladder is the ninth most common malignant disease and the thirteenth most common cause of cancer death worldwide 1 . Indeed, 76,960 new cases of bladder cancer and 16,390 deaths attributable to bladder cancer were predicted to occur in 2016 in the United States alone 2 . In 2012, 429,793 cases of bladder cancer were diagnosed and 165,084 deaths were recorded globally 3 . Men are more affected than women (3.2:0.9 ratio) and disease incidence increases with age 1 . The most common symptom of bladder cancer is either microscopic or macro scopic (visible) blood in the urine (haema turia), which occurs in 13.7% and 78.3% of patients, respec tively 4 . Among patients with bladder cancer, macro scopic haema turia is associated with advanced pathological stage. However, many patients with microscopic haema turia are not adequately evaluated and there is no active screening for bladder cancer 5 . Bladder cancer generally originates from the epithe lium (urothelium) that covers the inner surface of the bladder, and urothelial carcinomas represent the most common type of bladder cancer. Bladder cancers with variant histology (that is, with distinct histomorpho logical phenotypes) have also been described (10-25% of cases) 6 and include squamous cell carcinoma, smallcell carcinoma and adenocarcinoma. Highgrade urothe lial carcinomas can be of micropapillary, sarcomatoid, plasmacytoid, nested and microcystic variants and have the propensity for divergent differentiation into, for example, squamous and glandular histologies. Variant histology bladder cancers are associated with locally aggressive disease, metastasis and poor response to exist ing therapies; however, controversy persists over the true influence that histology has on outcomes. In general, individualized management should be applied to these patients in the light of the currently limited literature.
. Among patients with bladder cancer, macro scopic haema turia is associated with advanced pathological stage. However, many patients with microscopic haema turia are not adequately evaluated and there is no active screening for bladder cancer 5 . Bladder cancer generally originates from the epithe lium (urothelium) that covers the inner surface of the bladder, and urothelial carcinomas represent the most common type of bladder cancer. Bladder cancers with variant histology (that is, with distinct histomorpho logical phenotypes) have also been described (10-25% of cases) 6 and include squamous cell carcinoma, smallcell carcinoma and adenocarcinoma. Highgrade urothe lial carcinomas can be of micropapillary, sarcomatoid, plasmacytoid, nested and microcystic variants and have the propensity for divergent differentiation into, for example, squamous and glandular histologies. Variant histology bladder cancers are associated with locally aggressive disease, metastasis and poor response to exist ing therapies; however, controversy persists over the true influence that histology has on outcomes. In general, individualized management should be applied to these patients in the light of the currently limited literature.
Tumours that invade the detrusor muscle are con sidered muscleinvasive bladder cancer (MIBC) and are more likely to metastasize to lymph nodes or other organs. Approximately 75% of newly diagnosed patients have nonmuscleinvasive bladder cancer (NMIBC) and 25% have MIBC 7 or metastatic disease 8 (FIG. 1) . The stage at diagnosis of bladder cancer has not changed over the past 10 years based on data from the Surveillance, Epidemiology, and End Results (SEER) registry in the United States because active screening is not available. Accordingly, mortality rates have not changed as there is no cure for metastatic disease 9 . The Cancer Genome Atlas (TCGA) project has advanced our understanding of bladder cancer 10 . This genetic characterization study of MIBC has provided information not only on the genetic drivers that might serve as therapeutic targets but also on the subtypes or clusters of invasive disease. These clusters might be associ ated with prognostic factors and unique therapeutic approaches, and might eventually provide a step for ward towards individualized patient management. In this Primer, we discuss urothelial bladder cancer epidemiology, pathophysiology, diagnosis, screening and prevention as well as management and quality of life issues.
Epidemiology

Incidence and mortality
The incidence of bladder cancer differs considerably between geographical regions such that agestandardized incidence (ASI) is almost three times greater in more developed countries (ASI of 9.5 per 100,000 population) than in lessdeveloped countries (ASI of 3.3 per 100,000 population) (TABLE 1) . The highest ASI is observed in European countries (namely, Spain, Italy, Denmark and Switzerland), North America, some northern African countries (for example, Egypt) and western Asia (Turkey and Israel), particularly in men 11 . By contrast, the lowest rates were noted in Central and South America, Sub Saharan Africa and Southeast Asia 11 . Urothelial cancers remain the most common type of bladder cancer in North America and Europe; however, in Egypt, 10-40% of bladder cancers are squamous cell cancers that are associated with infections with blood flukes (schisto somiasis; also known as bilharzia) 12 . The introduction of efficient antibilharzia drugs together with increased prevalence of cigarette smoking has resulted in a signifi cant decline in the incidence of squamous cell cancer but a shift towards more urothelial cancers in Egypt in recent years 11 . Although rates of bladder cancer are higher in white populations than in other ethnicities, survival is worse for black individuals 8, 13 , a finding shown in the United States and São Paulo, Brazil 14 . Unfortunately, information about incidence in black populations around the world is gen erally lacking. The low rates in Africa can be attributed to access to health care and competing risks of mortality 11 . Additionally, global variations of bladder cancer mor tality are less conspicuous than those of incidence. This reduced variability might result from the similar manner by which patients with advancedstage cancers are diag nosed and registered in health care systems 15 . However, differences in regional mortality reflect, at least in part, the disparate access to modern health care systems, sen sitive diagnostic facilities and the latest treatment pro tocols. Fortunately, at the global level, agestandardized bladder cancer mortality has declined recently, especially in the most developed countries. Exceptions include Central and South America (for example, Brazil and Cuba), some central, southern and eastern European countries (for example, Bulgaria, Croatia, Hungary and Romania) as well as the Baltic countries (for example, Latvia), which have experienced rapid economic transi tion over the past 15 years. However, according to the WHO, the number of bladder cancer cases and deaths are anticipated to almost double in the near future 16 . This phenomenon is explained by the increase in life expec tancy over time, as most bladder cancer is diagnosed at >65 years of age. The average life expectancy has increased by 3% since 1950, and the life expectancy gap between moredeveloped and lessdeveloped countries has diminished by 4.9 years since 2000 (REF. 17 ).
Risk factors
Cigarette smoking is the most common risk factor for bladder cancer. Indeed, reported estimates indicate that tobacco is responsible for half of all cases 18 ; however, a lag time of 20-30 years is evident between cigarette expo sure and diagnosis 19 . Current bladder cancer incidence is highest, albeit not uniformly, in regions that had high smoking rates in the 1980s 11, 20 . In particular, in Spain and in Italy, agestandardized smoking rates in 1980 amounted to 44.4% and 44.3%, respectively; the highest bladder cancer incidence in men in these countries was 36.7 per 100,000 in 2003 and 33.2 per 100,000 in 2007. Since then, smoking prevalence has declined substan tially in highincome countries, and incidence and mor tality have tended to mirror this trend 11 . Thus, smoking patterns may partially explain geographical diversities in bladder cancer epidemiology. Unfortunately, the WHO has reported increases in tobacco consumption in large areas of the lessdeveloped world, including Africa, the Middle East, eastern Europe, countries of the former Soviet Union and Asia, where governmental control over the cigarette market (including marketing) is less stringent, and public awareness of the detrimental effects of tobacco is lacking 21 . In addition to cigarette smoking, associations between several environmental factors and bladder cancer have been extensively investigated. Diets low in fruits and vegetables, and urban living are all linked -although not invariably -to increased bladder cancer risk 22, 23 . Furthermore, some evidence suggests that alcohol intake slightly increases the risk, but epidemiological data are confounded by other risk factors 24 . Metabolic syndrome in men was also reported to influence bladder cancer risk, but no direct or indirect association has been conclusively shown with either risk or prognosis 25 . Consumption of water or food polluted with arsenic might explain some regional bladder cancer data. For example, arsenic pollution was correlated with bladder cancer risk in Argentina, Chile and Bangladesh 8, 26 . Ambient air pollu tion is also suggested to influence bladder cancer risk in less developed countries. Direct combustion chem icals (mainly from diesel and gasoline engine exhausts, station ary power plants and indoor air pollution) are major sources of ambient air pollution 26 .
Occupational exposure to carcinogens has long been associated with bladder cancer risk. According to analy ses, the greatest risk of bladder cancer develop ment occurs in industrial areas processing paint, rubber, petroleum products and dyes, whereas the greatest risk for bladder cancerspecific mortality occurs in elec trical and chemical process workers 23, 27 . Along with widespread urbanization, many manufacturing pro cesses are being transferred from moredeveloped to lessdeveloped countries, potentially posing increased occupational hazards for the local workers. Nevertheless, no more than 8% of bladder cancer cases are thought to be attributable to such exposures 28 , and the global impact of occupational risks on bladder cancer inci dence to explain geographical diversity remains to be fully elucidated. Additionally, unemployment, number of physically unhealthy days, number of days exposed to air pollution ozone, proportion of houses with water derived from wells, employment in the mining indus try, urban living and ethnicity are all linked to bladder cancer mortality 23, 24, [26] [27] [28] . Some evidence supports a genetic predisposition to bladder cancer; genes involved in the metabo lism of carcinogens, such as Nacetyltransferase, and GSTM1null genotypes are associated with increased risk 29 . Specifically, women with a history of smoking cigarettes and who harbour the GSTM1null genotype are more prone to developing bladder cancer than their nonsmoking counterparts 13 . Large genomewide associ ation studies (GWAS) have found sequence variants that can increase the risk for bladder cancer; for example, alterations in the urea transporter encoded by SLC14A1 are associated with renal urine concentration and can influence the contact of carcinogens with urothelial surfaces [30] [31] [32] [33] [34] . Furthermore, on the basis of a novel, bio informatics analysis that measured gene-gene inter actions in two GWAS, bladder cancer susceptibility was purportedly associated with decarboxylase protein complexes 35 , which are potential druggable targets.
Mechanisms/pathophysiology
Pathological and clinical information from mouse mod els and human samples indicate that urothelial carci noma develops via two distinct pathways, giving rise to papillary NMIBCs and nonpapillary (solid) MIBCs (FIG. 2) . In mouse models, lowlevel expression of mutant Hras gives rise to flat or papillary urothelial hyper plastic lesions, whereas highlevel expression leads to NMIBCs 36 . Similarly, in humans, the predicted precur sors of NMIBC are flat or papillary urothelial hyperplas tic lesions. Two common alterations in NMIBC, deletion of chromosome 9 and a point mutation in FGFR3 (which encodes fibroblast growth factor receptor 3), are also evi dent in these hyperplastic precursors [37] [38] [39] ; when a papil lary NMIBC from the same patient was studied, these alterations were shared [37] [38] [39] , suggesting a clonal relation ship between the precursor and the tumour. Urothelial papilloma, which is considered a benign tumour, also shows frequent FGFR3 mutations 40 . By contrast, generation of (solid) MIBCs in mouse models requires the inactivation of one or more of the tumour suppressor genes. These genes include Trp53, Nature Reviews | Disease Primers . The most important grade differentiation is between low-grade and high-grade tumours (that is, the greater propensity for invasion). Notably, although CIS is confined to the mucosa (that is, non-invasive), it has a pronounced propensity to progress to invasive stages and is characterized by an aggressive tumour biology 135 . PUNLMP, papillary urothelial malignancy of low malignant potential. Inset adapted with permission from REF. 65 , Macmillan Publishers Limited.
Rb1 and Pten [41] [42] [43] . Tumours in these mouse models are preceded by the development of flat urothelial dysplasia and carcinoma in situ (CIS) lesions. Similarly, in humans, high risk of development of MIBC in patients with dys plasia or CIS is well documented 44 , and these lesions share features with highgrade and invasive bladder cancers. These features facilitate cell proliferation and include mutations in TP53 (REF. 45 ) and stabilized TP53 expression 46 . Moreover, upregulated expression of CK20 and HER2 (also known as ERBB2) 47 , and reduced expression of PTEN with concomitant upregulation of the phosphatidylinositol 3kinase (PI3K) pathway 48 are shared features.
Clonality and cell of origin
Given that bladder cancer is typically a multifocal dis ease, questions have been raised concerning its clonality. Indeed, chronic exposure of the urothelium to carcino gens might lead to the development of multiple cancers from different cells of origin. Alternatively, multiple monoclonal lesions could arise from the seeding of cells liberated during surgery, intraepithelial expansion or spread from a single tumour clone.
In women with bladder cancer, the random inactiv ation of one X chromosome during embryogenesis provides an ideal cell of origin marker. Xinactivation analysis has indicated that although some multifocal or metachronous tumours are oligoclonal 49 , the majority are monoclonal 50 . However, other studies using multi ple molecular markers or genomewide features prov ide clear evidence for a subclonal evolution of tumours that are predicted to have arisen from a single cell of origin 51, 52 . Evidence from wholebladder mapping studies of MIBC shows that broad regions of the urothelium are replaced by the monoclonal expansion of cells that repre sent tumour precursors. In addition, subclonal molecu lar evolution within these populations enabled the construc tion of the temporal series of genomic events leading to tumour formation 53 . Indeed, large areas of the urothe lium with normal or dysplastic morpho logy represent clonal 'fields' of altered cells within which loss of hetero zygosity on 3q22, 5q22-23, 9q21, 10p26, 13q14 and 17q13 have been identified 53, 54 , all of which are common alterations in bladder cancer. The most detailed analysis so far has been carried out on a region spanning the RB1 locus on chromosome 13, which showed loss of hetero zygosity in the absence of RB1 mutations in urothelial fields that had minimal or no morphological change. Regional genes on chromosome 13 that have been pro posed to drive early clonal expansion included ITM2B, which was shown to be silenced by hypermethyl ation, with mutation of RB1 occurring as a secondary event during tumour progression 55, 56 . The tumourinitiating cells in NMIBC are thought to be those in the intermediate (that is, nonbasal) layers of the bladder wall 57 , findings supported by lineage tracing studies conducted in animals 58 . Lineagetracing studies performed in mice have also identified sonic hedgehog (Shh)expressing basal cells that can repopu late the normal urothelium following injury 59 and can give rise to MIBC in a carcinogeninduced mouse model 60 . Stem cells isolated from undifferentiated human bladder tumours also show a phenotype (CD44 + ,
KRT14
+ /KRT5 + , KRT20 − ) that is similar to cells that reside in the basal layer of the normal urothelium; these cells have tumourinitiating potential when implanted as xeno grafts 57, 61 . These different cells of origin for NMIBC and MIBC might determine or constrain the molecular events that subsequently occur during tumour develop ment. The differentiation markers of these cells of origin are apparent in the expression signatures of NMIBC and MIBC (see below).
Molecular landscape
Although bladder cancer is a smokingrelated cancer, recent genome sequencing studies have not found a predominant mutational signature of tobacco smoke exposure. Instead, a major contribution of APOBEC cytidine deaminases to the mutation signature has been detected in both NMIBC and MIBC 10, 62 . Despite similar mutational features, the mutational load and overall changes in genomic architecture in the two groups are distinct. Averages of 10, 64 . These differences in mutational landscape are accompan ied by major differences in the overall patterns of mutated genes in these two major groups of tumours (see below) 65 .
NMIBC. Most lowgrade tumours are genomically stable, and the most common copy number alteration is deletion of chromosome 9 (~50% of tumours) 66 . The CDKN2A locus (9p21) encodes p16 and p14 ARF , which are negative regulators of the RB pathway and p53 path way, respectively. Chromosome 9 loss also implicates TSC1, a tumour suppressor that regulates mechanistic target of rapamycin (mTOR) signalling (see below). Genomewide copy number analyses have also identified deletions of chromosome arms 10q, 11p, 11q, 17p, 18q, 19p and 19q in up to 20% of cases, most involving entire chromosome arms 64, 67 . Gain of 20q has been reported, but highlevel DNA amplification is infrequent in this tumour group.
Most cases of NMIBC are characterized by activating point mutations in FGFR3 (REF. 68 ). In cultured normal human urothelial cells, expression of mutant FGFR3 leads to activation of the RAS-mitogen activated pro tein kinase (MAPK) pathway and a phenotype of cell overgrowth at confluence, suggesting that FGFR3 acti vation might contribute to early urothelial hyperplasia 69 . FGFR3 is also activated in some cases by chromo somal translocation. The fusion proteins resulting from these translocations show loss of the final exon of FGFR3 and fusion inframe to TACC3 (which encodes trans forming acid coiledcoil containing protein 3) or, less commonly, to BAIAP2L1 (which encodes brainspecific angiogenesis inhibitor 1associated protein 2like 1). These fusion proteins are potent transforming onco genes 70, 71 . Activating mutations in RAS gene family members are also found in some NMIBCs; these muta tions and FGFR3 mutations are mutually exclusive 72 . Consequently, it is estimated that activation of the RAS-MAPK pathway may contribute to development of >80% of NMIBCs (TABLE 2) . Activating mutations in PIK3CA are also common in NMIBC and frequently occur with FGFR3 mutations [73] [74] [75] . Inactivated tumour suppressor genes include TSC1 (9q34), which is mutated in ~15% of cases 73 . A few mutations in TSC2 have also been reported 76 . The TSC1-TSC2 complex regulates the mTOR branch of the PI3K pathway; loss of one copy and/or mutation of TSC1 in many of these tumours suggests that upregu lated mTOR signalling is a major feature of NMIBC. Frequent inactivating mutations in the cohesin complex tumour suppressor gene STAG2 are also character istic of NMIBC 77, 78 . However, the role of STAG2 loss in generating aneuploidy, as reported in other tumour types, is unlikely to be important in these genomically stable tumours 63, 77 . Wholeexome sequencing has also revealed inactivating mutations in several genes that encode chromatinmodifying proteins, including KDM6A, CREBBP, EP300 and ARID1A. These inactiv ating mutations are present at significantly higher fre quencies than in any other cancer type, including in MIBC 10, 62, 63, 79 , indicating that epigenetic alterations are likely to play a major part in shaping the phenotype of these tumours (TABLE 3) .
MIBC.
The genome of MIBC typically shows complex copy number changes and rearrangements, and synchro nous and metachronous MIBCs are often genomically divergent, suggesting rapid subclonal evolution. Many regions of genomic amplification have been reported, some containing genes with known oncogenic function, for example, E2F3, MDM2 and HER2 (TABLE 2) . Regions of homozygous deletion include 9p21 (p16 and p14 ARF ), 10q23 (PTEN), 2q36, 4q35 and 13q14 (RB1) 10, 64, 67, 80 . MIBCs share many molecular features with other solid cancers, particularly loss of function of key tumour suppressors (TABLE 3) , leading to escape from cell cycle checkpoints and dysregulation of major sig nalling pathways. TP53 and RB1 are frequently mutated, and regulators of their pathways are also altered 10 (for example, amplification of MDM2 and E2F3 and homozygous deletion of CDKN2A). Hemizygous dele tion, homozygous deletion and/or reduced expression of PTEN is found in many cases 73, 81 . Other mutations in genes encoding components of the PI3K pathway include those in TSC1, AKT1 and PIK3CA (at lower Nature Reviews | Disease Primers frequencies than in NMIBC) 82 . The upstream pathway activator HER2 is amplified, mutated or overexpressed in a subset of cases 10 . In particular, high frequency of HER2 amplification and mutation occurs in the micropapillary variant 83 . Although FGFR3 mutations are less frequent in MIBC than in NMIBC, up to 40% of MIBCs show upregulated expression 84 . Isoform switching (generated by alternative splicing of specific exons) of FGFR3 and FGFR1 are prevalent in MIBC 85, 86 , with predicted effects on ligand binding and potential for increased autocrine or paracrine signalling. Activation of FGFR1 can induce epithelial-mesenchymal transition (EMT, whereby cells acquire migratory and invasive properties) in pre clinical models 87 , suggesting that FGFR1 has a potential role in MIBC metastasis. In addition to FGFR signalling in these tumours, RAS mutations and mutational inactiv ation of NOTCH pathway genes 88 also contribute to MAPK pathway activation. Mutations in APC, nuclear accumulation of βcatenin (encoded by CTNNB1) and loss of expression of the WNT antagonists secreted frizzled receptor proteins (SFRPs) and WNT inhibitory factor 1 (WIF1) 89, 90 also implicate the WNT signalling pathway in some MIBCs 91, 92 . Similar to NMIBC, epigenetic changes clearly play a major part in MIBC development 10 ; genomewide analy sis has indicated the importance of both DNA methyl ation and histone methylation in gene silencing 93 . Extensive analyses of chromatin marks and their association with expression and mutational status have not yet been carried out. However, a role for histone modification in regions of copynumberindependent gene silencing identified in aggressive MIBC with a CISassociated expression signature has been demonstrated 94 . Distinct differences in DNA methylation exist between NMIBC and MIBC, with common hypomethyl ation in nonCpG islands in NMIBC and widespread promoter hypermethyl ation in MIBC 95, 96 . Many specific DNA methylation changes have clinical and pathological associations 97 . Finally, some molecular features in MIBC are report edly related to response to chemotherapy. For example, tumours with HER2 mutations show good response to neoadjuvant chemotherapy 98 . In addition, response to cisplatinbased chemotherapy is related to the presence of mutations in ERCC2 (REF. 99 ). ERCC2 encodes a DNA helicase with a key role in nucleotide excision repair. Tumours harbouring ERCC2 mutations have a higher mutational load than other MIBCs 10 , and are associ ated with the presence of a distinct genomic signature prevalent in MIBCs from smokers 100 .
Molecular subtypes
Heterogeneity in the clinical outcomes of patients sug gests that biologically relevant subtypes might exist within and between NMBIC and MIBC.
Transcriptional profiles currently provide the best defined subtypes. The subtypes described, their relation ships and biological implications have been compared analytically 101, 102 and discussed in detail in recent reviews 103, 104 . The initial Lund study of tumours of all grades and stages defined the following five subtypes: urobasal A, genomically unstable, (immune cell) infil trated, squamous cell carcinomalike and uro basal B 105 . These subtype assignments did not absolutely correlate with tumour grade and stage, which might have highly relevant prognostic implications 105 . Subsequently, three major transcriptional profiling studies focused on MIBC 10, 106, 107 and one focused on NMIBC 108 . To date, these classifications have used different nomen clatures (FIG. 3) . Although bioinformatics approaches have facili tated possible alignment of these profiles to reveal overlaps, it will be essential to assess which signatures provide the most clinically useful information and to develop a unified nomenclature system to describe these signatures.
Subtypes based on DNA copy number alterations and on DNA methylation profiles have also been described, some with prognostic associations 64, 109 . Three subtypes based on mutations and regions of DNA amplification and deletion were reported in a TCGA study of MIBC 10 . How well these TGCAbased subtypes align with the transcriptional subtypes is currently unclear. However, it is anticipated that integration and unified description of epigenetic, copy number and transcriptional data will ultimately deliver data with improved clinical relevance. NMIBC. In the Lund study 105 , lowgrade Ta tumours were predominantly classified as urobasal A. These tumours were characterized by high levels of mark ers of urothelial differentiation, cell adhesion genes, an FGFR3related signature and early cell cycle genes such as CCND1 (which encodes cyclin D1). Genomically unstable tumours exhibited high expression of late cell cycle genes, such as those encoding the cyclin family members B and E, but retained markers of urothelial dif ferentiation, including uroplakins. Infiltrated tumours showed high levels of expression of immune cell and stromal markers compatible with a high proportion of nontumour cells in the sample. Stage T1 and high grade tumours contained fewer urobasal A tumours and more genomically unstable and infiltrated tumours (subtypes that show overlap with the broad luminal subtype of MIBC, see below); however, some were classi fied as urobasal B and squamous cell carcinomalike (both basallike groups).
The UROMOL study 108 (using samples from 460 patients with lowgrade and highgrade Ta and T1 tumours and CIS) described three expression classes (FIG. 3) . Class 1 tumours contained many Ta tumours and patients with this type showed the best progno sis among the three classes. Class 1 lesions were simi lar to the urobasal A group of the Lund study. Class 2 tumours contained more T1 and highgrade tumours and tumours from patients with high European Organisation for Research and Treatment of Cancer (EORTC) risk score for recurrence and progression 110 . This class also included the majority of patients who pro gressed to MIBC. Indeed, the majority of MIBC samples analysed in parallel were assigned to this class 108 . Class 2 tumours were also characterized by the expression of late cell cycle, EMTrelated, stemcellrelated and CIS signature genes 111 , but retained the expression of uro plakins. This result implied that these characteristics may represent tumours of origin for luminal MIBC cells that retain markers of urothelial differentiation. Indeed, FGFR3activated MIBCs frequently have dele tions of CDKN2A 10, 101 , and homozygous deletion of CDKN2A can be used to identify a subset of patients with FGFR3mutant NMIBC with high risk of progres sion 112 . Class 3 tumours shared features with the uro basal A subtype (including FGFR3 mutations), but also had features of the basal signature defined in MIBC 106 (that is, a phenotype of KRT5 MIBC. MIBC analyses have identified two major groups of tumours that have been termed 'luminal' and 'basal' (subtyping defined by the University of North Carolina, USA), which show strong similarities to subtypes defined in breast cancer 113 . Further subdivision into three 107 (subtyping defined by the MD Anderson Cancer Center (MDA), USA) or four 10 (subtyping defined by the TCGA) categories provides further biological insight into and relationships with disease outcome (FIG. 3) .
MIBC luminal tumours commonly show papillary histology and express markers of urothelial differentiation (such as the uroplakins and KRT20), Ecadherin (encoded by CDH1), FGFR3 and early cell cycles genes (for exam ple, CCND1). Also expressed are the transcription factors peroxisome proliferatoractivated receptorγ (PPARG), . Data also indicate that the MDA TP53like subtype, which con tains tumours with overlap with both luminal and basal types, is associated with a high frequency of resistance to neoadjuvant chemotherapy 107 . Several actionable therapeutic targets segregate with specific expression subtypes. These targets include FGFR3 and HER2 in luminal tumours, epidermal growth factor receptor (EGFR) in tumours with squa mous differentiation and immune checkpoint inhib itors in basal tumours with evidence of high immune infiltration. The potential role for EGFR inhibition in basal subtype tumours has been examined in depth, and preclinical evaluation (in human cell lines and in mouse models) provides support for this approach 115 .
A specific signature for claudinlow basal tumours has recently been defined that is related to low PPARG and high nuclear factorκB (NFκB) activity; these tumours are enriched for a tumourinitiating cell expression sig nature 61 , have an EMT phenotype and high immune infiltration. Accordingly, these tumours might respond to immune checkpoint inhibition 116 . Given this poten tial prognostic and therapeutic relevance, it is impor tant to develop methods that can rapidly assign subtype member ship using routine clinical samples. Recent efforts to identify these subtypes using conventional histopathology and immunohistochemistry 117, 118 could facilitate this endeavour.
Diagnosis, screening and prevention
Signs and symptoms
Most patients are diagnosed because of (painless) haema turia; the incidence of bladder cancer is 10-20% in patients with macroscopic haematuria and 2-5% in referred populations with microscopic haematuria 119, 120 . Usually, microscopic painless haematuria is incidental in urine tests performed for a general health assessment.
Bladder cancer can also be suspected if the patient presents with nonspecific symptoms of the lower urinary tract associated with impaired storage of urine, namely, increased urinary urge, frequency and dysuria. These symptoms are more frequent in patients with CIS than with papillary (pathological Ta) tumours and should prompt urological assessment 4, 121, 122 . Urine analysis, by dipstick or microscopy or both, should indicate the presence of haematuria and rule out urinary tract infec tion, which can mimic and/or cooccur with bladder cancer. Accordingly, following treatment of urinary tract infection, absence of these symptoms and haematuria must be confirmed 123 .
Evaluation and diagnosis
Evaluation of patients suspected of having bladder cancer is performed using cystoscopy (FIG. 4) , which is an out patient endoscopic procedure performed with a flex ible scope and with local anaesthesia 124 . Any abnormal finding, such as reddish flat, papillary or solid lesions, requires histological evaluation because benign condi tions, such as inflammatory diseases, can mimic bladder cancer. Histology can be obtained by transurethral biopsy or resection of the entire area (see Management). Often, inspection of cells in the urine (cytology) is performed as an adjunct measure to detect missed cancer; cells with malignant appearance are highly indicative of the pres ence of cancerous lesions in the bladder and again warrant cystoscopic and histological investigation. Currently, no urinarybased tumours markers have demonstrated suffi cient sensitivity and specificity to replace cystoscopy in the detection of bladder cancer 121, 125, 126 . Importantly, CIS is an entity that is challenging to diag nose cystoscopically because these lesions are difficult to discern from normal bladder tissue. Instead, microscopic urinary analysis is required to identify atypical cells 127 , and diagnosis is confirmed upon histological assessment of bladder tissue samples (FIG. 4) . Cystoscopic detection of CIS may be enhanced by fluorescence cystoscopy 128 or narrowband imaging 129 . These technologies improve the differentiation of tumorous lesions from normal tissue by taking advantage of the increased metabolic activity (blue light) and vessel architecture (narrow band) that occurs in cancer cells and have higher specificity for bladder cancers than traditional cystoscopy.
Imaging of the upper urinary tract, that is, the renal collecting system and the ureter, is an important compo nent of evaluation of patients with haematuria but plays a minor part in diagnosing bladder cancer. Although CT and MRI urography have been suggested to improve diagnostic accuracy, ultrasound imaging has been sug gested to suffice 121, 130 . In patients with confirmed MIBC, CT imaging is mandated to stage and assess potential distant spread 121 .
Staging and prognosis
Bladder cancer prognosis (and management) depends on bladder cancer histopathology (NMIBC or MIBC) 121, 131 . Indeed, histology is the only reliable determining factor of tumour biology to inform management. However, although prognostication cannot be exact, the depth of tumour infiltration into the bladder wall can provide a simple stratification of risk. For example, tumours con fined to the inner lining of the bladder (the mucosa) that do not invade the lamina propria are classified as stage Ta according to the Tumour, Node, Metastasis (TNM) classification system 131 (FIG. 1) . Tumours invad ing the lamina propria are classified as stage T1; these tumours are characterized by an adverse tumour bio logy similar to muscleinvasive tumours 132 . Tumours penetrating the bladder detrusor muscle and beyond are highly aggressive 131, 133 . Additionally, grading (the extent to which the cells are differentiated) is important for assessing Ta tumours because welldifferentiated (lowgrade tumours) are less aggressive than highgrade lesions 134, 135 . In 2016, a third edition of the WHO classification was issued, accentuating the changes proposed by the 2004 over the 1973 classifi cation (FIG. 1) . Although benefit over the 1973 classification has not yet been evaluated systematically, the current (2016) version provides uniform terminol ogies and clearer definitions, especially in the increasingly recognized divergent differentiation in MIBC.
Overall, the importance of histopathology in bladder cancer diagnosis, prognostication and treatment is clear. However, interobserver and intraobserver variability in staging and grading is a limitation of the technique. For example, significant interobserver variability in the classification of stage T1 versus Ta tumours and tumour grading using both the 1997 and 2004 criteria of the WHO classification have been reported 121, 132, 136 .
Screening and prevention
Screening to enable the early detection of bladder cancer is not available owing to the low incidence rates com pared with common cancers such as prostate cancer and breast cancer. However, several nonrandomized trials have demonstrated the ability to detect bladder cancer early using blood detection in the urine or urinebased tumour markers, such as cytology or nuclear matrix protein number 22 (NMP22), which reflects mitotic activity 137 . Although the value of, for example, urinary cytology, is clear in the followup care of patients with NMIBC (see below, Management), the low detection rates limit current application in a screening setting 138 . Additionally, screening has been proposed for individ uals at high risk of developing bladder cancer, for example, those with substantial exposure to risk factors, such as smokers. In contrast to other common malig nancies, genetic predisposition has little utility in pre dicting who will develop bladder cancer, but genetics do exert an influence via regulating the susceptibility to environmental risk factors 139 . Prevention of bladder cancer focuses on avoiding tobacco exposure as well as environmental and occupa tional carcinogens. Tobacco cessation is challenging, and many patients have difficulty in stopping smoking 140 . Physicians have an obligation to inform patients about the risks and to encourage tobacco cessation.
Management
Initially, all newly diagnosed bladder tumours require an endoscopic resection under general or spinal anaesthe sia. This procedure, transurethral resection of bladder tumour (TURBT), is performed to enable a thorough visualization of the bladder and appropriate resection with an attempt to include muscle for accurate staging. Various guidelines are available on managing bladder cancer, including from the European Association of Urology, the American Urological Association, Society of Urologic Oncology and US National Comprehensive Cancer Network 121, [141] [142] [143] [144] . Although generally concordant, these recommendations do have important differences owing to the varying levels of evidentiary support 143 . In general, NMIBCs are frequently managed with endo scopic resection and riskbased intravesical therapy (that is, bladder instillation), whereas MIBCs are managed with more aggressive treatments such as cystectomy (bladder removal) with or without chemotherapy.
TURBT TURBT has not only a diagnostic role but also a thera peutic one and can be a sufficient and potentially curative therapy depending on the pathological features of the tumour. TURBT is performed by passing an endo scopic instrument (a resectoscope) through the urethra. Small tumours can be resected en bloc with the electri fied wire loop of the resectoscope, whereas larger tumours are resected in multiple fractions. Patients with NMIBC can be stratified into three risk groups accord ing to the number of tumours, tumour size, recurrence rate, tumour stage, presence of CIS and tumour grade to further guide therapy after initial TURBT 144 (TABLE 4) .
Patients with lowrisk disease are often treated with the initial TURBT if all disease was visibly resected, but remain under close surveillance owing to risk of recurrence. Although many surveillance protocols have been recommended, at a minimum, cysto scopy should be performed 3 months postoperatively and at decreas ing frequencies for up to 5 years. Future lowgrade recurrences can be treated with TURBT or inoffice fulguration (heat ablation).
Understaging the true pathology at the initial TURBT in patients with highrisk disease is an important risk; there is an up to 20% chance of upstaging a patient with T1 disease to T2 even if muscle was present in the initially resected tissue, and up to a 40% chance of upstaging if muscle was not present 121 . Furthermore, even if the tumour is accurately staged at initial TURBT, there is a 50% chance of an incomplete resection result ing from factors such as multiplicity, size and location of the tumour 145 . True staging is of utmost important in bladder cancer to determine the appropriate treat ment after initial TURBT. Thus, a repeat TURBT is recommended within 2-6 weeks in patients with a known incompletely resected tumour or with tumours invading the lamina propria (T1 ; FIG. 1) , and should be considered in highgrade noninvasive disease (except CIS alone) to improve staging accuracy and increase recurrencefree survival 145, 146 . A randomized controlled trial (RCT) has shown that repeat TURBT after newly 148 . However, some issues with a high false positive rate that decreases with operator experi ence are limitations, and the proprietary equipment is costly. Nonetheless, this technology is promising with respect to improved diagnosis and treatment of NMIBC 149 . Bipolar electrocautery is another new technology that uses less energy and voltage than the standard mono polar cautery of the TURBT loop as the circuit does not pass through the patient. Additionally, isotonic fluids can be used that have minimal effects on the serum of the patient compared with monopolar resection (although this issue is less of a concern during bladder resections than, for example, when the technique is used to ablate prostate tissue) 150 . Other potential TURBT improvements being explored include minimizing the obturator muscle reflex in the pelvis, decreasing bladder perforation and reducing the effects of cautery artefacts on pathology; however, more trials are needed before conclusions can be drawn 151 .
Adjuvant intravesical therapy
In patients with intermediate and especially high risk disease (TABLE 4) , adjuvant intravesical therapy is advised. Bacillus Calmette-Guérin (BCG), a vaccine primarily used against tuberculosis, can both decrease recurrence and retard progression of bladder cancer and is reportedly superior to chemotherapy according to multiple RCTs and metaanalyses 152, 153 . Adjuvant therapy must include maintenance therapy for 1 year in intermediate risk disease and for up to 3 years (if toler able) for highrisk disease to achieve maximal efficacy; various protocols are available. BCG maintenance can lower the risk of progression by 37% compared with no BCG maintenance 154, 155 . Patients who have persistent or worsen ing disease after an appropriate treatment course with BCG, and those who experience disease relapse while on maintenance therapy are deemed BCG failures 156 . Failure of BCG therapy can also occur in those who experience recurrence with an inadequate treatment course owing to intolerable adverse effects 156 . For these patients, the most oncologically effective treat ment is radical cystectomy, although consideration can be given to bladder preservation strategies, including intravesical chemotherapy, deviceassisted intravesical therapy and clinical trials 157 . Following TURBT, a single dose of intravesical therapy with chemotherapeutic agents (mitomycin or doxoru bicin in the United States, as well as epirubicin or pirarubican in Europe) within 24 hours can decrease recurrence by 40% at 1 year and 15% at 5 years 158, 159 . Intravesical chemotherapy should be given to patients immediately following TURBT with papillary lesions if there is no clinical concern for MIBC or bladder perfor ation during TURBT 121 . If there is suspicion of bladder perforation, immediate intravesical therapy should not be given owing to the increased risk of complications 121 . The oncological benefit of adjuvant intravesical therapy is particularly useful in patients with lowrisk tumours, as those with intermediate and highrisk disease are at greater risk of recurrence and are likely to require further adjuvant therapy.
Radical cystectomy
Radical cystectomy is the goldstandard therapy for patients with MIBC as well as for those with NMIBC who fail intravesical treatment as defined above 141 . Furthermore, certain patients with T1 NMIBC (invasion of the lamina propria) can be considered for 'early' cys tectomy [131] [132] [133] . Early cystectomy can also be considered in patients with highrisk features on TURBT, for example, those with lymphovascular invasion, concomitant CIS, variant histology (especially micropapillary disease), large (>3 cm) and multifocal tumours, and deep lamina propria invasion 133, 160, 161 . Radical cystectomy typically includes prostatectomy in men and hysterectomy and partial resection of the vagina and urethra in women.
Although radical cystectomy is traditionally per formed with an open technique, there is increasing interest in minimally invasive approaches using the da Vinci (Intuitive Surgical, Sunnyvale, California, USA) robotic system. The potential benefits of this approach include reduced blood loss and other bene fits inherent in minimally invasive surgery, with multi ple studies demonstrating equivalent oncological and functional outcomes 162, 163 . One RCT compared robotic with open cystectomy with equivocal findings; however, only the cystectomy portion of the operation was per formed robotically and the urinary diversion portion (see below) was performed through a standard open incision 164 . Thus, the initial benefits of the robotic approach were potentially mitigated 164 .
Another RCT comparing open and radical cystectomy, the RAZOR trial, is currently recruiting candidates; however, again, the diversion can be performed through an open incision 165 . Further studies are needed to compare total robotic radical cystectomy with intracorporeal diversion with open radical cystectomy before further conclusions can be drawn 166 .
Lymphadenectomy. The role of lymphadenectomy (lymph node dissection) in managing bladder cancer is crucial, and although thorough lymphadenectomy has a demonstrated survival advantage, debate remains regarding the specific template that should be used or the number of lymph nodes that should be removed 167 . The standard dissection procedure includes removal of lymph nodes along the external iliac vessels from the circumflex iliac vein caudally up to the common iliac bifurcation cephalad and the genitofemoral nerve later ally to the ureter medially (FIG. 5) . In the extended template, the dissection is carried up along the common iliac vessel to the aortic bifurcation and presacral region; in the superextended template, the dissection reaches the aorta to inferior mesenteric artery. Given that most surgeons agree that at a minimum a standard lymph node dissection should be performed, a randomized trial (SWOG S1011) is evaluating the standard versus extended lymph node dissection templates and we await the results (NCT01224665).
Urinary diversion.
Following radical cystectomy and lymph node dissection, urinary diversion is required to reroute urine flow from its normal pathway 168 . All urin ary diversions use a segment of intestine to which the ureters are anastomosed and the other end is used to expel urine. Urinary diversions can be either continent, such as continent cutaneous diversions and orthotopic neobladders, or noncontinent, such as the ileal conduit. Ileal conduit diversions use a segment of ileum that is brought to the skin as a stoma; urine is collected in a urostomy bag. Continent cutaneous diversions vary in technique but essentially a 'pouch' is created from vari ous segments of intestine and a channel is brought out flush with the skin with some form of continent mech anism requiring catheterizing to empty. In an orthotopic neobladder, a pouch is created and anastomosed to the native urethra with patients voiding through their native orifice. This type of diversion requires adequate renal function and an absence of cancer at the urethral margin.
Recovery. Great strides have been made with respect to recovery after radical cystectomy resulting from the implementation of specific Enhanced Recovery after Surgery (ERAS) protocols 169 . Preoperatively, these path ways encourage fluid hydration and use of medications such as alvimopan, which is a μopioid antagonist that aids recovery after bowel surgery. These medications mitigate the bowelrelated adverse effects associated with opioid drugs and discourage routine bowel preparation that can lead to dehydration and the subsequent need for intravenous fluids that can lead to bowel oedema and ileus (obstruction). Intraoperatively, ERAS protocols minimize fluid resuscitation and encourage removal of any nasogastric tubes before extubation. Postoperatively, the protocols encourage early ambulation, early feeding (typically with a regular diet by the second post operative day) and the substitution and minimization of opioid pain medication for alternatives such as ketorolac, acetamino phen and tramadol. Such ERAS protocols have resulted in reduction of the length of hospital stay and faster convalescence 170 .
Survival. Following radical cystectomy, survival out comes largely depend on final pathological staging. The 10year recurrencefree survival for patients without lymph node involvement is 86% for pathologically con firmed T0 tumours, 76% for T1-pT3a, 61% for T3b and 45% for T4, but drops to 34% regardless of stage when lymph nodes are involved 171 . Bladder cancer remains a lethal disease. Indeed, despite radical cystectomy with seemingly good oncological outcomes, even in patients with apparently organconfined disease and negative margins and lymph nodes, many patients still experi ence recurrence thereby prompting consideration of adjuvant therapies.
Neoadjuvant chemotherapy
The role of neoadjuvant chemotherapy before radical cys tectomy to help improve survival has been investigated in several RCTs and metaanalyses. One metaanalysis of 11 trials reported a 5% survival advantage at 5 years 172 . These studies used platinumbased chemotherapy; there are insufficient data to support noncisplatinbased therapy in the neoadjuvant setting. Some adjuvant studies have shown similar efficacy with the lesstoxic gemcitabine-cisplatin combination, which has been extrapolated to the neoadjuvant setting 173 . Thus, in patients with MIBC (and particularly in those with clin ical >T3 disease), neoadjuvant chemotherapy should be given if they are able to tolerate a platinumbased regimen. If platinumbased chemotherapy cannot be tolerated, patients should proceed directly to radical cystectomy.
Adjuvant therapy
The role of adjuvant therapy following radical cystectomy remains unclear because individual studies hitherto have been underpowered. A recent RCT demonstrated no clear benefit in deferred versus immediate chemo therapy in patients with pathological >T3 disease or disease with lymph node involvement 174 . However, a metaanalysis including a total of 945 patients from 9 RCTs showed a 23% relative decrease in the risk of death with adjuvant gemcitabine-cisplatin compared with surgery alone. Similarly, a 34% reduction in the risk of disease recur rence was apparent from seven trials reporting this end point; the reduction was highest for those with positive lymph node involvement 175 . Early evidence suggests that adjuvant radiotherapy might have a role in patients with adverse pathological features (pathological >T3 disease, lymph node involvement or positive margins) on radical cystectomy and is being further explored in the NRGGU001 trial (NCT02316548) 176 .
Bladder preservation protocols for MIBC
Although radical cystectomy remains the gold stand ard for oncological efficacy in patients with MIBC, the surgery carries substantial quality of life implications; furthermore, some patients are not fit for surgery. Thus, various bladdersparing options have been explored that could benefit very carefully selected patients. Radical TURBT involves an aggressive endoscopic resection procedure to resect all visible disease (while taking care not to cause a perforation), and cautery (either mono polar or bipolar) is used to ablate tissue as deep and wide as possible in an attempt to destroy as much tumour as safely possible. Radical TURBT as a standalone treatment approach can have a durable effect on survival but should only be considered for patients who are not eligible for radical cystectomy or chemoradiation 177 . Survival data of 133 patients have revealed a satisfactory cancer specific survival (76.7%) and progressionfree survival with bladder preservation (57.8%) at 15 years. However, com plete tumour resection (confirmed by negative biopsy of the tumour bed) is crucial for this type of management 177 . Partial cystectomy can be cautiously considered for patients with a small (<3 cm), solitary tumour at the bladder dome with no associated CIS or tumours in a diverticulum 178 . One study compared 86 patients who underwent partial cystectomy with patients who under went radical cystectomy in a matchedpair fashion (1:2 ratio), but found no significant difference in 10year cancerspecific survival (58% versus 63%; P = 0.63) or overall survival (36% versus 39%; P = 0.67).
Trimodal therapy combines radical TURBT with concomitant radiosensitizing chemotherapy and exter nal beam radiotherapy 179 . This strategy can result in 5year cancerspecific survival rates of 50-82%; however, 25-30% of patients require salvage cystectomy due to failure to respond to therapy 180 . Importantly, trimodal therapy severely limits the likelihood of future ortho topic neobladder diversion should salvage radical cystec tomy be required, a limitation that must be discussed when counselling patients.
Metastatic disease
Patients diagnosed with metastatic bladder cancer during their initial workup or after radical cystectomy are treated with systemic chemotherapy. The stan dard firstline regimens are cisplatin based and include the following combinations: methotrexate, vinblastine, doxoru bicin and cisplatin (MVAC); cisplatin, metho trexate and vinblastine (CMV); gemcitabine-cisplatin; or gemcitabine-cisplatin plus paclitaxel. Patients not eligible for cisplatinbased therapy can be treated with carboplatin or with taxanes, which might be inferior 181 .
In patients with disease progression following platinum based chemotherapy, some secondline options are available, albeit with mixed results
182
. The role of systemic immunotherapy in patients with metastatic bladder cancer has yielded some promising initial results with checkpoint inhibitors (see below, Outlook). One such drug, atezolizumab (a programmed cell death protein 1 (PD1) inhibitor) has been approved for secondline treatment and is now being investigated for firstline treatment 183 . Meanwhile, studies are ongoing of pembrolizumab (NCT02560636, NCT02662062 and NCT02500121), nivolumab (NCT01928394 and NCT02387396) and ipilimumab (NCT02553642 and NCT01524991) in patients with metastatic bladder cancer.
Quality of life
Patients with bladder cancer face numerous potential challenges to quality of life owing to their disease and available treatments. Overall function and wellbeing as well as the specific domains of sexual, urinary and bowel function can be affected. Furthermore, high rates of recurrence and progression imposes one of the high est costs per person of all cancer types 184 . Patients with NMIBC contend with a high recurrence rate, low but variable rates of progression and frequent -often life long -invasive monitoring and intravesical treatments. Patients with MIBC face the potentially lifealtering options of radical cystectomy with urinary diversion.
A growing body of literature describes the quality of life of these patients. Most of the data relate to the MIBC patient population, specifically around questions of the impact of urinary diversion type. For example, one sys tematic review suggested more favourable results for con tinent orthotopic diversion than for ileal conduit in studies published since 2012 (REF. 185 ). The existing literature is limited by heterogeneity in study design, with different questionnaires, frequently retrospective or crosssectional data collection and few baseline data. Currently, five bladder cancerspecific patientreported outcome (PRO) instruments have been described (three of which have been validated) to further the goal of capturing patients' experience with these disease and treatment processes. Questionnaires are focused on the experience of those with NMIBC 186, 187 , MIBC 188 and either NMIBC or MIBC 189 . A recent review details the methodological and contextual strengths and limitations of these instruments 190 .
Recently, ERAS protocols focusing on perioperative care with the components of reduced bowel preparation and standardized feeding schedule and analgesic regi men came into practice 191, 192 . In the only RCT to date, the ERAS protocol reduced postoperative morbidity in terms of woundhealing disorders, fever and thrombosis compared with a conservative regimen 193 . Time spent in the intermediate care unit was significantly reduced and quality of life determined using the EORTC QLQ30 questionnaire was significantly better postoperatively for those on the ERAS protocol. Larger trials are needed to validate these findings; improved perioperative manage ment will probably mitigate some of the morbidity associated with diversion procedures.
A growing body of experience supports the value of collecting PROs in routine care, ideally integrated into the electronic medical record (ePROs) 194 . Multiple pro spective studies have demonstrated improved patient satisfaction, symptom management, quality of life and patient-clinician communication with the integration of ePROs into routine cancer care [195] [196] [197] [198] . As these efforts gain traction and PRO data become routinely collected, bladder cancer care might improve in multiple dimen sions 199 . Routine ePRO data collection could also be aggregated over time across diverse patient populations to inform our understanding of the comparative effec tiveness of different bladder cancer treatment options. Ultimately, further development in this area could lead to the establishment of PRObased quality perfor mance measures for bladder cancer, based on standards established by the US National Quality Forum.
Outlook
Although tobacco use is decreasing in some parts of the world, the impact of tobacco exposure can last for decades such that bladder cancer incidence is fairly stable and might increase as the population ages. Improving survival for bladder cancer will require earlier detec tion, more effective local control or new therapies for metastatic disease.
Diagnosis and biomarkers
Two techniques are emerging to detect bladder cancer earlier. The first option is to screen highrisk patients, which has proved challenging owing to low incidence and lack of genetic markers for susceptibility. Indeed, the cost of designing an RCT to demonstrate survival benefit of screening is extremely high. The second option is to improve detection by improving compliance with current guidelines for evaluating haematuria. Current guidelines are frequently ignored 200 , but it is possible that incorpor ation of risk stratification tools using clinical informa tion or urinebased tumour markers could enhance early detection 201, 202 .
Emerging classes of urinary markers using DNA methyl ation and microRNAs (mi RNAs) are currently being studied. For example, a recent review reported that urine markers of methylation revealed sensitivity in the range of 65-100% and specificity in the range of 77-100% in the detection setting 203 . Similarly, sensitivity of assess ing mi RNAs exfoliated from bladder cancer cells was 71-94%, with specificity in the range of 51-100% 203 . Another model assessing expression of IGFBP5, HOXA13, MDK, CDK1 and CXCR2 in a voided urine sample (geno typic data) and age, sex, frequency of macroscopic haema turia and smoking history (phenotypic data) was able to correctly stratify 80% of patients with micro scopic haema turia who did not have bladder cancer so they could avoid full urological workup 204 . Incorporating markers into the detection of bladder cancer will require validation to reduce the risk of falsenegative results. However, identifying patients at high risk of cancer will improve detection if that patient was not going to be evaluated in the first place.
The role of sex steroids and their specific receptors is an emerging research area in the progression of bladder cancer 205 . This idea originates from epidemiological stud ies showing that women are diagnosed with higher stage disease and have poorer outcomes after treatment than men 206 . Furthermore, early age at meno pause (≤45 years versus ≥50 years) is associated with an increased risk of bladder cancer 207 , whereas parous women, women who reported late menarche (≥15 years of age) and women who have used oestrogen and progestin therapy have lower risk of bladder cancer than women who have not been treated for menopause 208 . Data from basic science studies have shown that one of the most probable mechanisms for tumour progression involves UDP glucuronosyltrans ferase 1 (UGT1A) 209 , an enzyme vital for the detoxification of major carcinogens such as aromatic amines. UGT1A is differentially regulated by oestrogens and has a protective role in normal urothelium but decreased levels are associ ated with recurrence and cancer progression in the neo plastic urothelium 209 . UGT1A has been identified as being regulated by the androgen receptor transcription factor (at least in prostate tissue 210 ), and androgen mediated signals promote bladder carcinogenesis by downregu lating the expression of UGTs 211 . This finding was also supported by a clinical study evaluating the relationship between bladder cancer and androgen deprivation ther apy 212 . Of 162 patients having both prostate cancer and NMIBC, 22% who received androgen depriv ation ther apy experienced bladder cancer recurrence compared with 50% in the control group after a median followup of 62 months, and 5year actuarial recurrencefree sur vival was 76% versus 40%. Consequently, the potential role of sex steroids or their specific receptors might open the doors for new targeted therapies for bladder cancer.
Surgery
Technological advances in visualizing tumours using fluorescence cystoscopy and narrowband imaging are likely to improve detection and reduce recurrences due to inadequate initial resection. Furthermore, radical sur gery and extent of lymphadenectomy for MIBC are still evolving. Recent studies have shown that the extent of lymphadenectomy is more important than lymph node count; for example, two recent metaanalyses revealed that extended lymphadenectomy might contribute to 5year recurrencefree survival, despite patients having worse preoperative factors, in the extended lymphaden ectomy group compared with the standard lympha denectomy group 167, 213 without increasing the overall complication rates. There are two randomized controlled studies (SWOG 1011 (NCT01224665)) and Association of Urogenital Oncology and German Urological Association (NCT01215071) that will help to guide optimal surgical anatomical boundaries.
Since the introduction of the da Vinci surgical robot two decades ago, evidence has accumulated regarding the outcomes of robotassisted radical cystectomy compared with conventional open surgery. Three RCTs, albeit with limited numbers of patients, showed that only intra operative blood loss is better in robotassisted radical cys tectomy compared with open radical cystectomy 164, 214, 215 . Moreover, the study by Bochner et al. 164 was terminated early after the intentiontotreat analysis failed to demon strate a 20% decrease in perioperative complications according to the hypothesis. Despite the lack of superior ity of robotassisted surgery in these early experiences, the outcomes of the multiinstitutional, randomized, prospective, noninferiority phase III RAZOR trial are awaited before making a precise judgement regarding the future of robotassisted surgery in terms of peri operative and oncological outcomes in the management of MIBC 165 .
Intravesical therapies
Tumours frequently recur despite BCG induction and maintenance therapy, and the absence of effective treatments in this setting results in cystectomy being recom mended in many patients before development of muscleinvasive disease. Accordingly, new treat ments are being evaluated for use in patients with BCGunresponsive disease, some of which involve the use of viruses for therapeutic purposes. Oncolytic viruses that target cancer cells are being explored for bladder cancer 216 . Additionally, modified adenovirus that prod uces interferon α2b (IFNα2b) to stimulate the host immune system is also being explored in bladder cancer 217 . In a phase I study, adenovirusmediated IFNα2b gene therapy was administered by bladder instil lation in 17 BCGunresponsive patients; of the 14 patients treated with adequate dosage, 6 (43%) experienced com plete response with an average duration of 31 months and 2 were disease free at the last followup 218 . In another study, 5 of 7 patients treated with an augmented dose of the gene therapy were diseasefree after a minimum followup of 23.9 months 219 .
Systemic therapies
Whether the new molecular subtypes (FIG. 3) have an effect on response to chemotherapy is being examined. One study demonstrated that a significant number of patients with highgrade disease (67%) with the MDA luminal cell type were sensitive to neaoadjuvant MVAC chemotherapy, whereas those with the TP53like subtype were resistant to neoadjuvant chemotherapy 107 . Another group reported that somatic mutations in ERCC2 corre late with response to cisplatinbased therapy in MIBC 99 . Accordingly, prediction of response to neoadjuvant chemotherapy using the genetic background of the resected tumour is a new fruitful area for cancer research. Indeed, a clinical trial of neoadjuvant treatment (SWOG 1314) has been initiated to compare gemcitabinecisplatin with MVAC and the ability of a gene expression profilingbased algorithm (CoXEN) to predict complete pathological response.
In the TCGA analysis, 69% of bladder tumours harboured potentially druggable mutations, including 42% with alterations in the PI3K-AKT-mTOR pathway and 45% with alterations in the pathways mediated by MAPK (including HER2). Patients with specific target able mutations can have longterm responses to targeted therapies, which are ineffective when given to patients without the mutations 220 . Future trials such as NCImatch (NCT02465060) will hopefully shed light on effective strategies to treat patients in a personalized fashion and to identify agents that are effective in selected patients.
As briefly mentioned, checkpoint inhibitors are being explored as potential therapies in bladder cancer, building on advances in other cancer types. The major targets are cytotoxic T lymphocyteassociated antigen 4 (CTLA4), PD1 and programmed cell death ligand 1 (PDL1), which function to dampen inflammatory immune responses to prevent unregulated destructive inflammation 221 (FIG. 6) .
Another promising area of research is the combination of radiotherapy with immunotherapy. This strategy aims (PDL1-PD1), PDL2-PD1, CD80-CTLA4 (cytotoxic T lymphocyte-associated antigen 4), CD86-CTLA4 and CD276 (also known as B7-H3, the receptor for which is unknown) axes has shown promise in other cancer types and is actively being explored in bladder cancer. By contrast, promoting T cell-stimulatory pathways (for example, the CD137L-CD137 and CD40-CD40L axes) is also an option. Finally, engineering T cells to display chimeric antigen TCRs (such as CART-19) that have enhanced persistence is also being explored. OX40, also known as TNFRSF4; TCR, T cell receptor. to use immunotherapeutic agents, such as checkpoint inhibitors, to augment the immune response (socalled cytokine storm) triggered by tumour cell death induced by radiotherapy 221 . Studies of pembrolizumab in high risk and recurrent NMIBC are ongoing (NCT02324582, NCT02808141 and NCT02625962) but no clinical data are available in conjunction with radiotherapy.
Atezolizumab is a monoclonal antibody against PD1 that was approved by the US FDA in May 2016 for patients with metastatic bladder cancer who are unresponsive to platinumbased chemotherapy. In a phase II study (n = 310 patients), four categories of immune infiltration were defined: IC3 (whereby ≥10% of the tumour area is infiltrated), IC2 (≥5% and <10%), IC1 (≥1% and <5%) and IC0 (<1%). Atezolizumab treatment resulted in a significantly improved RECIST v1.1 objective response rate for each prespecified group (IC2-3: 27% (95% CI: 19-37%; P < 0.0001) and IC1-3: 18% (95% CI: 13-24%; P = 0.0004)) and in all patients (15% (95% CI: 11-20%; P = 0.0058)) compared with a historical control overall response rate of 10% 222 . Tumourinfiltrating immune cells expressing a high level of PDL1 were associated with higher response rates to atezolizumab. Moreover, 84% of the patients responding to therapy exhibited ongoing responses after a median followup of 11.7 months. Despite these findings, some reservations abound for the use of PDL1 as a predictive biomarker and for the use of PD1 or PDL1 inhibitors. These reservations are attributed to the multitude of PDL1specific antibodies, assays, scor ing systems and thresholds for positivity. Eventually, these classes of drugs along with targeted agents may provide more avenues for treatment of patients with advancedstage disease 223 . Overall, exciting times are forthcoming for bladder cancer care, with advances in understanding and manage ment of bladder cancer promising to be translated to improved survival and quality of life.
